Riso Pharmaceuticals International
Bioadvantex
Urixin
Silexin
Biolyse
Paclitaxel
BioSyent Inc.
FeraMAX
Feldan
Glenwood
Helsinn
Gelclair
Klean-Prep
Nasaleze Ltd.
Nasaleze
Omega laboratories
Pamidronate
PISA
Serral Laboratories
Stella Pharmaceutical Canada Inc.
Kolik-Gripe Water
Unigene
Fortical
 
Gelclair

 

GELCLAIR® has a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis. It is a concentrated oral gel available in single use packets of 15 ml each.

GELCLAIR® bioadherent oral gel helps patients who are undergoing radiation or chemotherapy (or a combination of the two) by relieving the pain of oral mucositis. GELCLAIR® is composed of three key ingredients that combine to provide pain relief to the mucosal surface of the mouth:

  • Polyvinylpyrrolidone (PVP) protects the mucosa

  • Hyaluronic acid (sodium hyaluronate) hydrates and soothes the mucosa

  • Glycyrrhetinic acid (licorice root extract) is a mild flavoring agent gentle on the mucosa

    GELCLAIR® is designed to be

    • Non-numbing

    • Non-stinging

    • Non-drying

    Adapted from Cawley

    GELCLAIR® coats the exposed nerve endings of the mucosa throughout the phases of oral mucositis

GELCLAIR® provides rapid and durable pain relief. Study results show that GELCLAIR® significantly reduces oral mucositis pain for 5 to 7 hours after administration.11

Short-Term results

In an open label study 30 patients experienced a 92% reduction in mean overall oral pain associated with lesions of the mouth and oropharyx 5 to 7 hours after treatment (p<0.005)11,12

 Open-label study of 30 patients with painful lesions of the mouth and oropharynx associated with chemotherapy, radiation, mucositis, HIV disease, severe diffuse aphthous ulcers, or oral surgery.  Pain was scored on a Visual Numerical Scale ranging from 0 (no pain) to 10 (worst pain), with scores recorded at baseline and at 5 to 7 hours after treatment.  GELCLAIR® was administered TID.11

GELCLAIR® helps patients restore the ability to eat and drink more normally.11,12

Medium-term results
in the same open label study 87% of patients reported reduced pain associated with swallowing foods, liquids, and saliva after 7 days of use (p<0.005)11,12

GELCLAIR® helped reduce pain associated with eating and drinking.11,12

Safety Profile

GELCLAIR® has a favorable safety profile:10

  • Generally well-tolerated

  • No known drug interactions

No adverse events have been reported in clinical trials with the use of GELCLAIR®. Postmarketing reports have included infrequent complaints of a burning sensation in the mouth.

 
 

Riso Pharma Tech is a Canadian-based specialty pharmaceutical company focused on in-licensing late-stage and approved molecules for marketing and sales in Canada, certain European Union countries, Latin America, and the Middle East.

 

From large multi-national pharmaceutical companies to small biotechs, Riso's license deals have yielded successful product launches in its territories. Five regional offices and over 360 employees worldwide enable Riso to extend the reach of our partner companies' products.

 

With an extensive track record of greater than 10+ years marketing and sales success in its territories, and thanks to Riso's financial strength, Riso is aggressively pursuing new in-licensing opportunities across several therapeutic areas: oncology, supportive care, neurology, endocrinology and women's health.